(IMCR) Immunocore Holdings plc Porters Five Forces Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IMCR) Immunocore Holdings plc Complete Analysis Pack
Elevate Your Analysis with the Complete Porter's Five Forces Analysis
This Immunocore Holdings plc Porter's Five Forces Analysis helps you understand the company’s competitive environment, including rivalry, buyer power, supplier power, substitutes, and new entrants. The page already shows a real preview of the actual report content, so you can see what you’re getting before buying. Purchase the full version for the complete ready-to-use analysis.
Suppliers Bargaining Power
Specialized biologics inputs
In FY2025, Immunocore Holdings plc’s T-cell receptor therapies still depend on GMP-qualified biologic reagents, cell-culture inputs, and controlled raw materials from a narrow vendor pool. That gives suppliers some leverage, because swapping a source can take 6-12 months for testing and requalification. Still, this power is capped by long-term supply controls and dual-sourcing where possible.
Dependence on contract manufacturers
Immunocore Holdings plc depends on specialized CDMOs and GMP partners for biologics output, so supplier power stays high when capacity or batch release is tight. In this market, validation history and regulator track record often matter more than price, because a failed tech transfer or supply gap can delay clinical or commercial doses by quarters. That makes continuity a bigger bargaining lever than unit cost.
Regulatory-grade quality requirements
Regulatory-grade quality rules narrow Immunocore Holdings plc’s supplier pool because inputs for pharma and clinical use must meet GMP and GCP controls, so only a few vendors can qualify. A single batch-consistency or compliance failure can delay a trial cohort or shipment by weeks, which lifts incumbent supplier power. That matters even more when Immunocore is scaling its 2025 clinical and commercial supply chain under strict release testing.
Key technology and assay providers
Immunocore Holdings plc relies on specialized testing, analytics, and bioinformatics across oncology and infectious disease work, so key technology and assay vendors can have moderate leverage. When only a few providers can deliver validated potency, stability, and safety tools, switching costs rise and timelines can slip. One missed assay can delay a study by weeks.
- Few validated vendors, higher leverage
- Specialized assays raise switching costs
- Critical work can delay programs
Potentially moderate overall supplier power
Immunocore Holdings plc faces potentially moderate supplier power because it can spread risk across more than one vendor, but its precision manufacturing and strict GMP quality needs still narrow the field. In biotech, switching a qualified supplier is slow, so raw materials, specialty reagents, and contract manufacturing partners can still push on price and terms.
The company can soften that pressure with dual sourcing, long-term contracts, and tighter inventory planning, but supplier leverage does not disappear. For a complex biologics model, even small disruptions can affect batch release timing, so supplier power stays meaningful rather than weak.
- Not locked to one supplier base
- Precision manufacturing limits alternatives
- GMP rules make switching slow
- Dual sourcing can reduce risk
- Supplier power stays moderate
Immunocore’s Supplier Power Stayed Moderate in FY2025
In FY2025, Immunocore Holdings plc’s supplier power stayed moderate because GMP-qualified reagents, specialty analytics, and CDMO capacity come from a narrow vendor base. Switching can take 6-12 months, so continuity and validation history matter more than price. Long-term contracts and dual sourcing help, but they do not remove the bottleneck.
| Driver | FY2025 signal |
|---|---|
| Switching time | 6-12 months |
| Supplier pool | Narrow, GMP-limited |
| Power level | Moderate |
What is included in the product
Detailed Word Document
Assesses Immunocore Holdings plc’s competitive pressures, supplier and buyer power, new entrants, and substitutes shaping profitability.
Customizable Excel Spreadsheet
A quick, investor-ready view of Immunocore’s five competitive forces—ideal for faster biotech strategy decisions.
Reference Sources
Shows the credible sources behind key claims, making the Immunocore Holdings plc reference trail easy to verify and use in decisions.
Customers Bargaining Power
Hospital and specialist prescriber influence
KIMMTRAK’s uptake is driven by oncologists, specialty centers, and protocol-based care, so buyers have real leverage over prescribing. In 2025, Immunocore still relied on one marketed product, which makes formulary access and clinical preference especially important. Because treatment sits in concentrated specialist pathways, hospital and prescriber power stays high.
Payer and reimbursement pressure
Insurers and national health systems can set prior auth, step edits, and price caps, so Immunocore Holdings plc may not realize list price even when clinical need is high. Uveal melanoma is rare, at about 5,000 new U.S. cases a year, which gives payers more leverage on net price than on volume. NICE and other HTA bodies can also block or delay access unless discounts and evidence packages are strong.
Small patient population reduces volume power
Uveal melanoma is rare, at about 5-7 cases per million people each year, so Immunocore Holdings plc sells to a small patient pool. That limits any one buyer’s ability to push for deep volume discounts. Still, most demand runs through a few specialist cancer centers and payers, so those channels can keep real negotiating power over price and access.
Clinical value supports pricing power
KIMMTRAK’s clinical benefit reduces customer pushback: in the phase 3 trial, median overall survival was 21.6 months versus 16.9 months with investigator’s choice, so buyers have less room to substitute or demand deep discounts. Uveal melanoma is rare, with about 5,000 cases a year in the U.S., and that unmet need supports premium pricing. That still only partly offsets buyer power.
- 21.6 vs 16.9 months median OS
- Rare cancer limits alternatives
- Premium pricing is easier to defend
Overall buyer power is moderate to high
Overall buyer power is moderate to high. Immunocore Holdings plc sells to specialist hospitals and sophisticated payers that demand strong clinical and health-economics evidence, so they can shape market access, price, and where a therapy sits in treatment lines.
That pressure is stronger beyond early adopters, where reimbursement rules matter more than science alone. In Immunocore Holdings plc’s 2025 reporting cycle, KIMMTRAK remained the key revenue driver, so payer pushback on one product can still move the whole base.
- Specialist buyers set evidence hurdles
- Payers influence price and access
- Treatment placement can be restricted
- Power rises outside early adopters
Specialist Buyers Hold Strong Leverage Over KIMMTRAK
Customer power is moderate to high for Immunocore Holdings plc because KIMMTRAK is sold through a small set of specialist centers and payers that can control access, prior auth, and net price. In 2025, one-product dependence made that leverage matter more. Rare uveal melanoma, about 5,000 U.S. cases a year, limits volume but not buyer pressure.
| Metric | Latest data |
|---|---|
| U.S. uveal melanoma cases | ~5,000/year |
| Lead product | KIMMTRAK |
| Buyer set | Specialists, payers |
| Buyer power | Moderate to high |
Preview Before You Purchase
Immunocore Holdings plc Porter's Five Forces Analysis
This preview shows the exact Immunocore Holdings plc Porter's Five Forces Analysis you’ll receive after purchase—no samples, no placeholders. The document is fully written, professionally formatted, and ready to use immediately. What you see here is the complete deliverable, so once you buy, you get instant access to this same file.
Rivalry Among Competitors
Focused oncology competition
Immunocore faces intense rivalry in oncology, where large biopharma and fast biotech teams chase the same unmet needs with novel immunotherapies. Even with differentiated TCR science, the fight is crowded: oncology R&D spending across the industry stayed near record highs in 2025, and rivals keep pushing into the same melanoma, solid tumor, and rare cancer niches. That makes pricing, data wins, and trial speed critical.
Platform race in T-cell engagers
Immunocore Holdings plc faces intense platform race pressure because its T-cell receptor approach competes with bispecific and other T-cell redirecting systems in solid tumors. KIMMTRAK remains the first and only approved T-cell receptor therapy in metastatic uveal melanoma, but rivals keep pushing better efficacy, safety, and dosing convenience. That constant innovation race raises the bar for every new trial and label expansion.
Pipeline breadth increases overlap
Immunocore Holdings plc faces tighter rivalry because two lead solid-tumor programs, IMC-C103C and IMC-F106C, broaden its overlap across NSCLC, ovarian, breast, and melanoma. These are among the same high-traffic oncology arenas where rivals already have late-stage assets, so head-to-head trial competition is intense. In 2025, oncology still drew the largest share of biotech R&D and deal value, which keeps pressure high.
Commercial stage but limited marketed footprint
KIMMTRAK gives Immunocore Holdings plc a real commercial base, but it still sells into one rare niche: metastatic uveal melanoma, a disease with only about 3,000 U.S. cases a year. That leaves the revenue base narrow, so Immunocore Holdings plc is not yet protected by a broad franchise. Bigger rivals with wider labels, deeper sales teams, or faster launch scale can still pressure future growth.
- One marketed drug, one main rare indication
- Small patient pool limits revenue breadth
- Broader competitors can outscale launches
Competitive rivalry is high
Competitive rivalry is high because biotech winners are set by patent life, Phase 2/3 readouts, and fast physician adoption. For Immunocore Holdings plc, the key test is proving clear clinical differentiation for KIMMTRAK, its only marketed drug, in HLA-A*02:01-positive uveal melanoma.
In this sector, one positive data release can quickly pull investor and partner attention away from rivals, so pricing power and pipeline value can shift fast. That makes rivalry intense for Immunocore Holdings plc, since its growth depends on beating other oncology immunotherapy programs on efficacy, safety, and label expansion.
- Patent timing drives biotech share gains.
- Clinical readouts can reprice stocks fast.
- KIMMTRAK is Immunocore Holdings plc's anchor asset.
- Superior differentiation is the main moat.
Immunocore Faces Fierce Rivalry in a Tiny, Fast-Moving Oncology Niche
Competitive rivalry is high for Immunocore Holdings plc because KIMMTRAK competes in a crowded oncology market where large biopharma and biotech groups are chasing the same solid-tumor targets. KIMMTRAK is still the only approved T-cell receptor therapy for metastatic uveal melanoma, but its moat is narrow because U.S. incidence is only about 3,000 cases a year. New data, faster trials, and cleaner safety can quickly shift share.
| Rivalry driver | Latest signal |
|---|---|
| KIMMTRAK market | Only approved TCR therapy; ~3,000 U.S. cases/year |
| Pipeline overlap | NSCLC, ovarian, breast, melanoma |
| Competition factor | Efficacy, safety, label expansion, speed |
Substitutes Threaten
Existing standard oncology therapies
Surgery, radiation, chemotherapy, and established systemic regimens still anchor first-line care across many cancers, so they remain strong substitutes for Immunocore Holdings plc’s newer immunotherapies. The pressure is highest where these options are cheaper, off-patent, and familiar to oncologists, especially in a market serving about 20 million new cancer cases a year worldwide.
Checkpoint inhibitors and other immunotherapies
Checkpoint blockade and other immunotherapies are strong substitutes for Immunocore Holdings plc in solid tumors. Merck’s Keytruda generated about $29.5 billion in 2024 sales, and Bristol Myers Squibb’s Opdivo brought in about $9.3 billion, showing how entrenched these options are. If an ADC or biologic has better efficacy or simpler dosing, physicians can shift fast and weaken demand for new entrants.
Cell and gene therapy alternatives
Cell and gene therapy alternatives raise the substitute threat because CAR-T, gene-modified cells, and other engineered therapies target the same high-value oncology niches that Immunocore Holdings plc serves. They are not direct swaps, but they can still pull clinical focus and capital away; in 2025, that kind of portfolio shift mattered as buyers favored platforms with broader tumor data and faster response rates.
Rare disease treatment options are limited but evolving
For uveal melanoma, direct substitutes are still scarce, which helps KIMMTRAK hold a strong niche. In the Phase 3 trial, KIMMTRAK delivered median overall survival of 21.7 months versus 16.0 months for control, showing why switching costs are high. Still, the field can shift fast if a new therapy beats this efficacy or improves safety.
- Few direct substitutes in uveal melanoma
- KIMMTRAK OS: 21.7 months vs 16.0 months
- Better future data could pressure demand
Threat of substitutes is moderate
Immunocore Holdings plc faces a moderate threat from substitutes because its T-cell receptor platform and targeted mechanism are differentiated, but patients and physicians can still choose from many oncology options, including checkpoint inhibitors, bispecifics, antibody-drug conjugates, and CAR-T. In 2025, this wide treatment pool kept switching pressure alive even where Company Name’s science is strong.
The threat stays moderate, not low, because alternative therapies exist across most target areas and payers still compare outcomes and cost.
- Differentiated TCR platform
- Many oncology substitutes exist
- Switching pressure remains real
Moderate substitute risk as KIMMTRAK holds a niche edge
Threat of substitutes for Immunocore Holdings plc is moderate: surgery, radiation, chemotherapy, checkpoint blockers, ADCs, bispecifics, and CAR-T all compete for the same oncology budgets. KIMMTRAK still has a niche in uveal melanoma, where median overall survival was 21.7 months versus 16.0 months in control, but payer and physician switching pressure stays real.
| Substitute | Signal |
|---|---|
| Checkpoint inhibitors | Keytruda sales: $29.5bn in 2024 |
| Uveal melanoma | KIMMTRAK OS: 21.7 vs 16.0 months |
Entrants Threaten
High scientific barriers
Immunocore Holdings plc faces a low threat from new entrants because biologic drug discovery needs rare skills in immunology, protein engineering, and translational medicine. Its TCR platform took years to build and validate, and it already has an approved product, KIMMTRAK, which raised the scientific bar for rivals. New firms must clear a long learning curve and heavy R&D spend before they can match this depth.
Heavy capital and time requirements
Immunocore Holdings plc faces a steep entry barrier because clinical development, manufacturing scale-up, and launch can take 6-8 years and cost tens of millions per program. Only about 1 in 10 drug candidates that enter clinical testing reaches approval, so late-stage failure risk is high. That scale of spend and risk keeps smaller biotech entrants out unless they have deep funding or a strong partner.
Regulatory and safety hurdles
New immune-oncology drugs face a high bar: they must clear Phase I-III trials and years of FDA or EMA review, often taking 6-10 years before launch. In 2025/2026, this is even tougher in immune-based oncology, where off-target effects can be severe and safety monitoring is strict, so easy market entry stays unlikely.
IP and know-how create protection
Immunocore Holdings plc’s proprietary TCR platform, patent estate, and years of clinical data make direct imitation hard. New entrants can chase other immunology routes, but copying the same binding logic and evidence base is costly and slow. That IP wall lowers new-entrant pressure.
- Patents protect core platform know-how.
- Clinical data raises replication cost.
- Alternative approaches are not direct copies.
Threat of new entrants is moderate
Threat of new entrants is moderate. Biotech still attracts start-ups, but Immunocore Holdings plc’s mix of T-cell receptor science, costly clinical work, and tight regulation is hard to copy; in 2025, the company still had only 1 approved product, which shows how steep the bar is.
Large pharma can still join through deals or M&A, so entry is possible, but de novo rivals face years of R&D and nine-figure trial spend.
- Science barrier stays high
- Capital needs are huge
- Deals beat greenfield entry
- Threat stays moderate
Immunocore’s Entry Barriers Stay High Despite Big Pharma Interest
Threat of new entrants for Immunocore Holdings plc stays low. A rival would need rare TCR science, 6-10 years of development and review, and heavy funding, while only about 1 in 10 clinical candidates reaches approval.
| Barrier | Why it matters |
|---|---|
| IP and data | Hard to copy KIMMTRAK and platform know-how |
| Capital | Late-stage trials can cost nine figures |
| Proof | Only 1 approved product in 2025 |
Big pharma can enter by deal or M&A, but greenfield entry remains tough.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.